Skip to content

Possible New Treatment for CF and NTM

Search Clinical Trials

Trial Objectives

Researchers in the ABATE Study are testing the safety of a drug called gallium nitrate for people with cystic fibrosis (CF) who also have been diagnosed with nontuberculous mycobacteria (NTM). Gallium nitrate is currently FDA-approved to treat high calcium in blood caused by cancer. Its use in treating people with CF is experimental, but gallium nitrate is thought to have antimicrobial properties that would help resolve NTM infections.

Who Can Participate

Adults 18 and older with CF and NTM who have a lung function of 25% or higher. To qualify, participants must not have received NTM treatment for at least two years.

Age: 18+ Gender: Any

Estimated Time Commitment

8 in-person visits, including two 5-day inpatient stays, and 4 phone calls over 28 weeks

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Alexandra Wilson

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Christopher H. Goss, MD MSc (University of Washington, Seattle Children's Hospital)

Principal Investigators

Jerry A. Nick

Jerry A. Nick, MD


  • Jane E. Gross

    Jane E. Gross, MD, PhD

  • Katherine Hisert

    Katherine Hisert, MD, PhD

  • Jennifer L. Taylor-Cousar

    Jennifer L. Taylor-Cousar, MD, MSCS

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required